title: FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?
authors.affiliation: Department of Medical Oncology & Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig-Maximilian-University, Munich, Germany. Electronic address: dominik.modest@med.uni-muenchen.de.
authors.forename: D P
authors.initials: DP
authors.lastname: Modest
authors.affiliation: Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of General, Visceral and Transplantation Surgery, University Hospital Aachen, Aachen, Germany.
authors.forename: U P
authors.initials: UP
authors.lastname: Neumann
authors.affiliation: Department of Surgery, Campus Charité Mitte|Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Pratschke
mesh_terms: D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols; D000068258:Bevacizumab; D002166:Camptothecin; D015179:Colorectal Neoplasms; D005472:Fluorouracil; D006801:Humans; D002955:Leucovorin; D008113:Liver Neoplasms; D009944:Organoplatinum Compounds
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin